ASA DAILY LOW DOSE TABLET (CHEWABLE)

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

ACETYLSALICYLIC ACID

Prieinama:

PHARMASCIENCE INC

ATC kodas:

B01AC06

INN (Tarptautinis Pavadinimas):

ACETYLSALICYLIC ACID

Dozė:

81MG

Vaisto forma:

TABLET (CHEWABLE)

Sudėtis:

ACETYLSALICYLIC ACID 81MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

30/120/180

Recepto tipas:

OTC

Gydymo sritis:

SALICYLATES

Produkto santrauka:

Active ingredient group (AIG) number: 0101169013; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2012-10-23

Prekės savybės

PRODUCT MONOGRAPH
ASA 81 MG
Acetylsalicylic
Acid Delayed-release Tablets USP
81 mg
ASA DAILY LOW DOSE
Acetylsalicylic
Acid Tablets USP
81 mg
Platelet aggregation inhibitor
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Quebec H4P 2T4
DATE OF REVISION:
March 14, 2022
www.pharmascience.com
SUBMISSION CONTROL NUMBER: 261509, 261543
Page 2 of 42
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................3
INDICATIONS AND CLINICAL USE
.........................................................................3
CONTRAINDICATIONS
.............................................................................................4
WARNINGS AND PRECAUTIONS
.............................................................................5
ADVERSE
REACTIONS..............................................................................................7
DRUG INTERACTIONS
..............................................................................................8
DOSAGE AND ADMINISTRATION
.........................................................................
10
OVERDOSAGE
.........................................................................................................
11
ACTION AND CLINICAL
PHARMACOLOGY.........................................................
11
STORAGE AND STABILITY
....................................................................................
13
SPECIAL HANDLING INSTRUCTIONS
................................................................... 13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................... 13
PART II : SCIENTIFIC INFORMATION
.........................................................................
15
PHARMACEUTICAL INFORMATION
.....................................................................
15
CLINICAL TRIALS
...........................................................................................